Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma

NCT01203618 is registered in ClinicalTrials.gov with Morphotek as lead sponsor.

NCT NCT01203618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01203618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma
Lead sponsor
Morphotek
Phase
Phase 2
Overall status
Withdrawn
Start date
February 28, 2011
Completion date
August 31, 2013
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable, non-functioning pituitary adenoma